Equillium reports fourth quarter and full year 2022 financial results and provides corporate & clinical development updates

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates.
EQ Ratings Summary
EQ Quant Ranking